28,180 Alzheimer's and dementia studies in plain English, each scored out of 100.
Citicoline has been extensively used for the treatment of neurodegenerative disorders associated with head trauma, stroke, brain aging, cerebrovascular pathology and Alzheimer's disease. 5 key findings →
Participants: 17 Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Lack of supportive evidence for SSRIs as cognition enhancers or disease modifiers in AD is the result of omissions in clinical trial design, as opposed to reporting of negative outcomes. 1 key finding →
Design: randomized controlled trial Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Alzheimer's disease (AD) is a central nervous system disorder characterized by the presence of neurofibrillary tangles, neuritic plaques and dystrophic neurones in susceptible areas of the brain. 1 key finding →
Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Forty-eight patients were randomized to treatment with either topiramate or risperidone, and 41 patients (21 of 25 in topiramate group and 20 of 23 in risperidone group) completed the trial. 4 key findings →
Participants: 41 Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Studies have shown that donepezil could reduce the AD assessment scale-cognitive subscale (ADAS-Cog) score in MCI patients and improve the patient's attention and speed of response; however, it also has many side effects. 3 key findings →
Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
The present study showed the potential use of IY intervention in reducing stress, anxiety, and depression. 3 key findings →
Design: randomized controlled trial Participants: 30 Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
When poor SRH was present we found no increased risk for NH placement or death among elderly people with mild AD. 3 key findings →
Design: randomized controlled trial Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Treatment outcomes in CitAD showed modest, although statistically significant, influence of genetic variation at HTR2A and HTR2C loci. 3 key findings →
Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Observational studies and pilot trials suggest that metformin may help prevent cognitive decline in neurodegenerative disorders. 3 key findings →
Participants: 326 Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Alzheimer disease (AD) is one of the most common diseases among the older adults. 5 key findings →
Participants: 45 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
We will evaluate the effectiveness and safety of combined NF-acupuncture therapy, and expect that it will serve as the basis for the use of NF together with acupuncture in the clinical setting. 1 key finding →
Participants: 22 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
We are currently in the recruitment and data collection phase. 1 key finding →
Design: cohort study Participants: 1,307 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Published results from the AN1792 trial may have underestimated the effect of vaccine on progression of cerebral atrophy among patients with an antibody response to the vaccine. 3 key findings →
Design: randomized controlled trial Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Arterial stiffness is a growing epidemic associated with increased risk of cardiovascular events, dementia, and death. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
With the aging of the population, the burden of Alzheimer's disease (AD) is rapidly expanding. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Vascular dementia is the second most common type of dementia. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
The global burden of ischaemic strokes is almost 4-fold greater than haemorrhagic strokes. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Dementia and gait impairments often coexist in older adults and patients with neurodegenerative disease. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Identification of modifiable risk factors provides a crucial approach to the prevention of dementia. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Caffeine stimulates central nervous system on a short term. 3 key findings →
Participants: 1,409 Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
It is broadly acknowledged that the onset of dementia in Alzheimer's disease (AD) may be modifiable by the management of risk factors. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
As the number of elderly persons in our country increases, more attention is being given to geriatric healthcare needs and successful ageing is becoming an important topic in medical literature. 2 key findings →
Design: longitudinal study Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
The incidence and prevalence of dementia are expected to increase several-fold in the coming decades. 3 key findings →
Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Dietary habits and vascular risk factors promote both Alzheimer's disease and cognitive impairment caused by vascular factors 1-3 . 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Executive function was associated with falls and gait speed slowing in older adults. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 28,180 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 28,180 records, built mostly from automated pulls of Europe PMC (61.7% of the library) and OpenAlex (18.1%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,034 records (3.7% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →